FMP
Turnstone Biologics Corp.
TSBX
NASDAQ
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
0.48 USD
0.01 (2.08%)
About
ceo
Dr. Sammy J. Farah M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://turnstonebio.comexchange
NASDAQ
Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
CIK
0001764974
ISIN
US90042W1009
CUSIP
90042W100
Address
9310 Athena Circle
Phone
347-897-5988
Country
US
Employee
80
IPO Date
Jul 21, 2023
Key Executives
